LEADER 04249nam 2200613Ia 450 001 9910829806003321 005 20220326012936.0 010 $a1-68367-095-7 010 $a1-283-65648-5 010 $a1-55581-717-3 035 $a(CKB)2670000000261697 035 $a(EBL)1039537 035 $a(OCoLC)811962835 035 $a(SSID)ssj0000720149 035 $a(PQKBManifestationID)11467334 035 $a(PQKBTitleCode)TC0000720149 035 $a(PQKBWorkID)10668468 035 $a(PQKB)11297948 035 $a(MiAaPQ)EBC1039537 035 $a(PPN)172571391 035 $a(EXLCZ)992670000000261697 100 $a20110616d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCandida and candidiasis$b[electronic resource] /$fedited by Richard A. Calderone, Cornelius J. Clancy 205 $a2nd ed. 210 $aWashington, DC $cASM Press$dc2012 215 $a1 online resource (544 p.) 300 $aDescription based upon print version of record. 311 $a1-55581-539-1 320 $aIncludes bibliographical references and index. 327 $aCover; Contents; Contributors; Preface; 1 Candida: What Should Clinicians and Scientists Be Talking About?; SECTION I: THE ORGANISMS, THEIR GENOMICS, AND VARIABILITY; 2 An Introduction to the Medically Important Candida Species; 3 Comparative Genomics of Candida Species; 4 The Genetic Code of the Candida CTG Clade; 5 Genome Instability and DNA Repair; 6 Switching and Mating; 7 Detection and Clinical Significance of Variability among Candida Isolates; 8 Cell Cycle and Growth Control in Candida Species; SECTION II: HOST-PATHOGEN INTERACTIONS (THE HOST); 9 Immunology of Invasive Candidiasis 327 $a10 Mucosal Immunity to Candida albicans11 Innate Immunity to Candida Infections; 12 Vaccines and Passive Immunity against Candidiasis; 13 Salivary Histatins: Structure, Function, and Mechanisms of Antifungal Activity; SECTION III: HOST-PATHOGEN INTERACTIONS THE PATHOGEN); 14 The Cell Wall: Glycoproteins, Remodeling, and Regulation; 15 Stress Responses in Candida; 16 Adhesins in Opportunistic Fungal Pathogens; 17 Encounters with Mammalian Cells: Survival Strategies of Candida Species; 18 Gene Expression during the Distinct Stages of Candidiasis; 19 Biofilm Formation in Candida albicans 327 $a20 Candida spp. in Microbial Populations and Communities: Molecular Interactions and Biological Importance21 Back to the Future: Candida Mitochondria and Energetics; SECTION IV: ANTIFUNGAL DRUGS, DRUG RESISTANCE, AND DISCOVERY; 22 Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use; 23 The Impact of Antifungal Drug Resistance in the Clinic; 24 Insights in Antifungal Drug Discovery; 25 Multidrug Resistance Transcriptional Regulatory Networks in Candida 327 $aSECTION V: CANDIDIASIS, EVOLVING DIAGNOSTICS, AND TREATMENT PARADIGMS26 Mucosal Candidiasis; 27 Systemic Candidiasis: Candidemia and Deep-Organ Infections; 28 New Developments in Diagnostics and Management of Invasive Candidiasis; 29 The Epidemiology of Invasive Candidiasis; SECTION VI: COOL TOOLS FOR RESEARCH; 30 Cool Tools 1: Development and Application of a Candida albicans Two-Hybrid System; 31 Cool Tools 2: Development of a Candida albicans Cell Surface Protein Microarray; 32 Cool Tools 3: Large-Scale Genetic Interaction Screening in Candida albicans 327 $a33 Cool Tools 4: Imaging Candida Infections in the Live Host34 Cool Tools 5: The Candida albicans ORFeome Project; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; U; V; W; X; Y; Z 330 $aThe underlying mechanisms of Candida and candidiasis and promising new directions in drug discovery and treatment. 606 $aCandidiasis 606 $aCandida 615 0$aCandidiasis. 615 0$aCandida. 676 $a616.969 701 $aCalderone$b Richard A.$f1942-$01717099 701 $aClancy$b Cornelius J$01717100 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910829806003321 996 $aCandida and candidiasis$94112950 997 $aUNINA